A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China

NCT05802862 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

414

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes

Interventions

DRUG: Insulin Degludec and Insulin Aspart

Sponsor

Sunshine Lake Pharma Co., Ltd.